Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steato… Read more
Viking Therapeutics Inc (VKTX) - Total Liabilities
Latest total liabilities as of December 2025: $76.67 Million USD
Based on the latest financial reports, Viking Therapeutics Inc (VKTX) has total liabilities worth $76.67 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Viking Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Viking Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Viking Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Viking Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Adani Green Energy Limited
NSE:ADANIGREEN
|
India | ₹967.93 Billion |
|
Kulicke and Soffa Industries Inc
NASDAQ:KLIC
|
USA | $289.61 Million |
|
President Chain Store Corp
TW:2912
|
Taiwan | NT$239.70 Billion |
|
Hanwha Solutions
KO:009830
|
Korea | ₩21.11 Trillion |
|
Prada S.p.A
PINK:PRDSF
|
USA | $6.34 Billion |
|
Gjensidige Forsikring ASA
OTCGREY:GJNSF
|
USA | $163.59 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Viking Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Viking Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Viking Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Viking Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $76.67 Million | +173.39% |
| 2024-12-31 | $28.04 Million | +39.72% |
| 2023-12-31 | $20.07 Million | -13.51% |
| 2022-12-31 | $23.21 Million | +164.38% |
| 2021-12-31 | $8.78 Million | -27.80% |
| 2020-12-31 | $12.16 Million | +70.35% |
| 2019-12-31 | $7.14 Million | +56.44% |
| 2018-12-31 | $4.56 Million | -47.30% |
| 2017-12-31 | $8.66 Million | +33.32% |
| 2016-12-31 | $6.49 Million | -3.30% |
| 2015-12-31 | $6.71 Million | -73.33% |
| 2014-12-31 | $25.17 Million | +5740.32% |
| 2013-12-31 | $431.00K | +308.86% |
| 2012-12-31 | $105.42K | -- |